Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111207

Cover Image

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111207

Global Glioblastoma Multiforme Treatment Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 414 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Web Access (Single User License) - Read Only
USD 4800
Web Access (Enterprise License) - Printable/Downloadable
USD 7000

Add to Cart

The glioblastoma multiforme treatment market is projected to register a substantial CAGR of 8.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Global Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary), Treatment (Surgery, Radiotherapy, Medications), Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administratin (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Israel, UAE, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the glioblastoma multiforme treatment market are:

Increasing prevalence of the disease

High incidence in emerging markets.

Market Players:

Some of the major players operating in the market are:

F. Hoffmann-La Roche AG

Amgen Inc.

Merck & Co., Inc.

Pfizer Inc.

Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare)

ZEISS International

Amneal Pharmaceuticals LLC

Elekta

Sun Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd.

Eckert & Ziegler

Accord Healthcare

Angiochem

ANI Pharmaceuticals, Inc.

Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.)

AstraZeneca

Cantex Pharmaceuticals, Inc.

CELON LABS

Diffusion Pharmaceuticals Inc.

EnGeneIC

ERC.SA.

Genenta science

Jazz Pharmaceuticals, Inc.

Loxo Oncology (A Subsidiary of Eli Lilly)

Novartis AG

VBL THERAPEUTICS

Viatris Inc.

Zydus Pharmaceuticals, Inc.,

TABLE OF CONTENTS

1 INTRODUCTION 54

  • 1.1 OBJECTIVES OF THE STUDY 54
  • 1.2 MARKET DEFINITION 54
  • 1.3 OVERVIEW OF GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET 54
  • 1.4 LIMITATIONS 56
  • 1.5 MARKETS COVERED 57

2 MARKET SEGMENTATION 60

  • 2.1 MARKETS COVERED 60
  • 2.2 GEOGRAPHICAL SCOPE 61
  • 2.3 YEARS CONSIDERED FOR THE STUDY 62
  • 2.4 CURRENCY AND PRICING 62
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
  • 2.6 MULTIVARIATE MODELLING 66
  • 2.7 TYPE LIFELINE CURVE 66
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
  • 2.9 DBMR MARKET POSITION GRID 68
  • 2.10 MARKET END USER COVERAGE GRID 69
  • 2.11 VENDOR SHARE ANALYSIS 70
  • 2.12 SECONDARY SOURCES 71
  • 2.13 ASSUMPTIONS 71

3 EXECUTIVE SUMMARY 72

4 PREMIUM INSIGHTS 76

  • 4.1 PESTEL 78
  • 4.2 PORTER'S FIVE FORCES MODEL 79

5 EPIDEMIOLOGY 80

6 PIPELINE ANALYSIS 82

7 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: REGULATORY SCENARIO 84

8 MARKET OVERVIEW 86

  • 8.1 DRIVERS 88
    • 8.1.1 GROWING PREVALENCE OF GLIOBLASTOMA MULTIFORME 88
    • 8.1.2 INCREASING RESEARCH AND DEVELOPMENT (R&D) 88
    • 8.1.3 PRESENCE OF A STRONG PIPELINE 89
    • 8.1.4 GROWING GERIATRIC POPULATION 90
  • 8.2 RESTRAINTS 91
    • 8.2.1 HIGH COST OF GLIOBLASTOMA MULTIFORME TREATMENT 91
    • 8.2.2 ADVERSE SIDE-EFFECTS OF GLIOBLASTOMA MULTIFORME TREATMENT 92
  • 8.3 OPPORTUNITIES 92
    • 8.3.1 INCREASING DRUG APPROVALS 92
    • 8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 93
    • 8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT 93
  • 8.4 CHALLENGES 94
    • 8.4.1 LACK OF NEW TREATMENT 94
    • 8.4.2 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS 94
    • 8.4.3 LACK OF EARLY DETECTION 95

9 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE 96

  • 9.1 OVERVIEW 97
  • 9.2 PRIMARY (DE NOVO) 100
  • 9.3 SECONDARY 100

10 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT 102

  • 10.1 OVERVIEW 103
  • 10.2 SURGERY 106
  • 10.3 RADIOTHERAPY 106
    • 10.3.1 BRACHYTHERAPY 107
    • 10.3.2 FRACTIONATED STEREOTACTIC RT (FSRT) 107
    • 10.3.3 CONFORMAL OR INTENSITY-MODULATED RT 107
    • 10.3.4 RADIOSURGERY 108
  • 10.4 MEDICATIONS 108
    • 10.4.1 TEMOZOLOMIDE 109
      • 10.4.1.1 ORAL 109
      • 10.4.1.1 INTRAVENOUS 109
    • 10.4.2 NITROSOUREAS DRUGS 109
      • 10.4.2.1 CARMUSTINE 110
        • 10.4.2.1.1 PARENTERAL 110
        • 10.4.2.1.2 IMPLANTABLE WAFERS 110
      • 10.4.2.2 LOMUSTINE 110
      • 10.4.2.3 NIMUSTINE 111
      • 10.4.2.4 FOTEMUSTINE 111
    • 10.4.3 TARGETED THERAPY 111
      • 10.4.3.1 BEVACIZUMAB 111
      • 10.4.3.2 OTHERS 111
    • 10.4.4 ANTI-EPILEPTICS 111
      • 10.4.4.1 LEVETIRACETAM 112
      • 10.4.4.2 PHENYTOIN 112
      • 10.4.4.3 CARBAMAZEPINE 112
    • 10.4.5 CORTICOSTEROIDS 112
      • 10.4.5.1 METHYLPREDNISOLONE 113
      • 10.4.5.2 PREDNISONE 113
      • 10.4.5.3 OTHERS 113

11 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE 114

  • 11.1 OVERVIEW 115
  • 11.2 ADULT 118
    • 11.2.1 MALE 118
    • 11.2.2 FEMALE 119
  • 11.3 GERIATRIC 119
    • 11.3.1 MALE 120
    • 11.3.2 FEMALE 120
  • 11.4 CHILD 120

12 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE 122

  • 12.1 OVERVIEW 123
  • 12.2 GENERICS 126
  • 12.3 BRANDED 126

13 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 128

  • 13.1 OVERVIEW 129
  • 13.2 PARENTERAL 132
  • 13.3 ORAL 132
    • 13.3.1 CAPSULES 133
    • 13.3.2 TABLETS 133
    • 13.3.3 POWDERS 133
  • 13.4 OTHERS 133

14 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER 135

  • 14.1 OVERVIEW 136
  • 14.2 HOSPITAL 139
  • 14.3 CLINICS 139
  • 14.4 HOME HEALTHCARE 140
  • 14.5 OTHERS 141

15 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL 142

  • 15.1 OVERVIEW 143
  • 15.2 HOSPITAL PHARMACY 146
  • 15.3 RETAIL PHARMACY 146
  • 15.4 ONLINE PHARMACY 147
  • 15.5 OTHERS 147

16 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION 149

  • 16.1 OVERVIEW 150
  • 16.2 NORTH AMERICA 156
    • 16.2.1 U.S. 166
    • 16.2.2 CANADA 170
    • 16.2.3 MEXICO 174
  • 16.3 EUROPE 178
    • 16.3.1 GERMANY 188
    • 16.3.2 FRANCE 192
    • 16.3.3 U.K. 196
    • 16.3.4 ITALY 200
    • 16.3.5 SPAIN 204
    • 16.3.6 RUSSIA 208
    • 16.3.7 SWITZERLAND 212
    • 16.3.8 NETHERLANDS 216
    • 16.3.9 HUNGARY 220
    • 16.3.10 POLAND 224
    • 16.3.11 AUSTRIA 228
    • 16.3.12 IRELAND 232
    • 16.3.13 NORWAY 236
    • 16.3.14 LITHUANIA 240
    • 16.3.15 TURKEY 244
    • 16.3.16 REST OF EUROPE 248
  • 16.4 ASIA-PACIFIC 249
    • 16.4.1 JAPAN 259
    • 16.4.2 CHINA 264
    • 16.4.3 INDIA 268
    • 16.4.4 AUSTRALIA 272
    • 16.4.5 SOUTH KOREA 276
    • 16.4.6 SINGAPORE 280
    • 16.4.7 THAILAND 284
    • 16.4.8 INDONESIA 288
    • 16.4.9 PHILIPPINES 292
    • 16.4.10 MALAYSIA 296
    • 16.4.11 VIETNAM 300
    • 16.4.12 REST OF ASIA-PACIFIC 304
  • 16.5 SOUTH AMERICA 305
    • 16.5.1 BRAZIL 315
    • 16.5.2 ARGENTINA 319
    • 16.5.3 PERU 323
    • 16.5.4 REST OF SOUTH AMERICA 327
  • 16.6 MIDDLE EAST & AFRICA 328
    • 16.6.1 SOUTH AFRICA 338
    • 16.6.2 U.A.E. 342
    • 16.6.3 EGYPT 346
    • 16.6.4 ISRAEL 350
    • 16.6.5 REST OF MIDDLE EAST AND AFRICA 354

17 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE 355

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL 355
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 356
  • 17.3 COMPANY SHARE ANALYSIS: NORTH AMERICA 357
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 358

18 SWOT ANALYSIS 359

19 COMPANY PROFILE 360

  • 19.1 F.HOFFMAN-LA ROCHE 360
    • 19.1.1 COMPANY SNAPSHOT 360
    • 19.1.2 REVENUE ANALYSIS 360
    • 19.1.3 COMPANY SHARE ANALYSIS 361
    • 19.1.4 PRODUCT PORTFOLIO 361
    • 19.1.5 RECENT DEVELOPMENT 361
  • 19.2 AMGEN INC. 362
    • 19.2.1 COMPANY SNAPSHOT 362
    • 19.2.2 REVENUE ANALYSIS 362
    • 19.2.3 COMPANY SHARE ANALYSIS 363
    • 19.2.4 PRODUCT PORTFOLIO 363
    • 19.2.5 RECENT DEVELOPMENTS 363
      • 19.2.5.1 PRODUCT APPROVAL 363
  • 19.3 MERCK & CO., INC 364
    • 19.3.1 COMPANY SNAPSHOT 364
    • 19.3.2 REVENUE ANALYSIS 364
    • 19.3.3 COMPANY SHARE ANALYSIS 365
    • 19.3.4 PRODUCT PORTFOLIO 365
    • 19.3.5 RECENT DEVELOPMENTS 365
      • 19.3.5.1 STRATETIC COLLABORATION 365
      • 19.3.5.2 EVENTS 366
  • 19.4 PFIZER INC. 367
    • 19.4.1 COMPANY SNAPSHOT 367
    • 19.4.2 REVENUE ANALYSIS 367
    • 19.4.3 COMPANY SHARE ANALYSIS 368
    • 19.4.4 PRODUCT PORTFOLIO 368
    • 19.4.5 RECENT DEVELOPMENT 368
      • 19.4.5.1 MERGER 368
  • 19.5 VARIAN MEDICAL SYSTEMS, INC. (A SUBSIDIARY OF SIEMENS HEALTHCARE) 369
    • 19.5.1 COMPANY SNAPSHOT 369
    • 19.5.2 REVENUE ANALYSIS 369
    • 19.5.3 COMPANY SHARE ANALYSIS 370
    • 19.5.4 PRODUCT PORTFOLIO 370
    • 19.5.5 RECENT DEVELOPMENT 370
      • 19.5.5.1 PARTNERSHIP 370
      • 19.5.5.2 ACQUISITION 371
  • 19.6 ZEISS INTERNATIONAL 372
    • 19.6.1 COMPANY SNAPSHOT 372
    • 19.6.2 REVENUE ANALYSIS 372
    • 19.6.3 PRODUCT PORTFOLIO 373
    • 19.6.4 RECENT DEVELOPMENTS 373
      • 19.6.4.1 PRODUCT EXPANSION 373
  • 19.7 AMNEAL PHARMACEUTICALS LLC 374
    • 19.7.1 COMPANY SNAPSHOT 374
    • 19.7.2 REVENUE ANALYSIS 374
    • 19.7.3 PRODUCT PORTFOLIO 375
    • 19.7.4 RECENT DEVELOPMENTS 375
      • 19.7.4.1 EVENT 375
      • 19.7.4.2 LAUNCH 375
      • 19.7.4.3 ACQUISITION 376
  • 19.8 ELEKTA 377
    • 19.8.1 COMPANY SNAPSHOT 377
    • 19.8.2 REVENUE ANALYSIS 377
    • 19.8.3 PRODUCT PORTFOLIO 378
    • 19.8.4 RECENT DEVELOPMENTS 378
      • 19.8.4.1 PARTNERSHIP 378
  • 19.9 SUN PHARMACEUTICAL INDUSTRIES LTD 379
    • 19.9.1 COMPANY SNAPSHOT 379
    • 19.9.2 REVENUE ANALYSIS 379
    • 19.9.3 PRODUCT PORTFOLIO 380
    • 19.9.4 RECENT DEVELOPMENT 380
      • 19.9.4.1 AGREEMENT 380
  • 19.10 TEVA PHARMACEUTICAL INDUSTRIES LTD 381
    • 19.10.1 COMPANY SNAPSHOT 381
    • 19.10.2 REVENUE ANALYSIS 381
    • 19.10.3 PRODUCT PORTFOLIO 382
    • 19.10.4 RECENT DEVELOPMENT 382
  • 19.11 ECKERT & ZIEGLER 383
    • 19.11.1 COMPANY SNAPSHOT 383
    • 19.11.2 REVENUE ANALYSIS 383
    • 19.11.3 PRODUCT PORTFOLIO 384
    • 19.11.4 RECENT DEVELOPMENT 384
  • 19.12 ACCORD HEALTHCARE 385
    • 19.12.1 COMPANY SNAPSHOT 385
    • 19.12.2 PRODUCT PORTFOLIO 385
    • 19.12.3 RECENT DEVELOPMENT 385
  • 19.13 ANGIOCHEM 386
    • 19.13.1 COMPANY SNAPSHOT 386
    • 19.13.2 PRODUCT PORTFOLIO 386
    • 19.13.3 RECENT DEVELOPMENT 386
      • 19.13.3.1 AGREMEENT 386
  • 19.14 ANI PHARMACEUTICALS, INC. 387
    • 19.14.1 COMPANY SNAPSHOT 387
    • 19.14.2 REVENUE ANALYSIS 387
    • 19.14.3 PRODUCT PORTFOLIO 388
    • 19.14.4 RECENT DEVELOPMENTS 388
      • 19.14.4.1 ACQUISITION 388
  • 19.15 ARBOR PHARMACEUTICALS, LLC. A SUBSIDIARY OF AZURITY PHARMACEUTICALS, INC. 389

19.15.COMPANY SNAPSHOT 389

    • 19.15.2 PRODUCT PORTFOLIO 389
    • 19.15.3 RECENT DEVELOPMENT 389
      • 19.15.3.1 ACQUISITION 389
      • 19.15.3.2 PRODUCT APPROVAL 390
  • 19.16 ASTRAZENECA 391
    • 19.16.1 COMPANY SNAPSHOT 391
    • 19.16.2 REVENUE ANALYSIS 391
    • 19.16.3 PRODUCT PORTFOLIO 392
    • 19.16.4 RECENT DEVELOPMENT 392
      • 19.16.4.1 AGREEMENT 392
  • 19.17 CANTEX PHARMACEUTICALS, INC. 393
    • 19.17.1 COMPANY SNAPSHOT 393
    • 19.17.2 PRODUCT PORTFOLIO 393
    • 19.17.3 RECENT DEVELOPMENT 393
  • 19.18 CELON LABS 394
    • 19.18.1 COMPANY SNAPSHOT 394
    • 19.18.2 PRODUCT PORTFOLIO 394
    • 19.18.3 RECENT DEVELOPMENT 394
  • 19.19 DIFFUSION PHARMACEUTICAL 395
    • 19.19.1 COMPANY SNAPSHOT 395
    • 19.19.2 SERVICES PORTFOLIO 395
    • 19.19.3 RECENT DEVELOPMENT 395
  • 19.20 ERC.SA 396
    • 19.20.1 COMPANY SNAPSHOT 396
    • 19.20.2 PRODUCT PORTFOLIO 396
    • 19.20.3 RECENT DEVELOPMENT 396
      • 19.20.3.1 PIPELINE UPDATE 396
  • 19.21 ENGENEIC 397
    • 19.21.1 COMPANY SNAPSHOT 397
    • 19.21.2 PRODUCT PORTFOLIO 397
    • 19.21.3 RECENT DEVELOPMENTS 397
      • 19.21.3.1 AWARDS 398
  • 19.22 GENENTA SCIENCE 399
    • 19.22.1 COMPANY SNAPSHOT 399
    • 19.22.2 PRODUCT PORTFOLIO 399
    • 19.22.3 RECENT DEVELOPMENT 399
      • 19.22.3.1 EVENT 399
  • 19.23 JAZZ PHARMACEUTICALS, INC. 400
    • 19.23.1 COMPANY SNAPSHOT 400
    • 19.23.2 REVENUE ANALYSIS 400
    • 19.23.3 PRODUCT PORTFOLIO 401
    • 19.23.4 RECENT DEVELOPMENT 401
      • 19.23.4.1 ACQUISITION 401
  • 19.24 LOXO ONCOLOGY (A SUBSIDIARY OF ELI LILLY) 402
    • 19.24.1 COMPANY SNAPSHOT 402
    • 19.24.2 PRODUCT PORTFOLIO 402
    • 19.24.3 RECENT DEVELOPMENT 402
  • 19.25 NOVARTIS AG 403
    • 19.25.1 COMPANY SNAPSHOT 403
    • 19.25.2 REVENUE ANALYSIS 403
    • 19.25.3 PRODUCT PORTFOLIO 404
    • 19.25.4 RECENT DEVELOPMENT 404
  • 19.26 VBL THERAPEUTICS 405
    • 19.26.1 COMPANY SNAPSHOT 405
    • 19.26.2 PRODUCT PORTFOLIO 405
    • 19.26.3 RECENT DEVELOPMENT 405
      • 19.26.3.1 EVENT 405
      • 19.26.3.2 AWARD 406
  • 19.27 VIATRIS INC 407
    • 19.27.1 COMPANY SNAPSHOT 407
    • 19.27.2 REVENUE ANALYSIS 407
    • 19.27.3 PRODUCT PORTFOLIO 408
    • 19.27.4 RECENT DEVELOPMENT 408
      • 19.27.4.1 AGREEMENT 408
  • 19.28 ZYDUS PHARMACEUTICALS, INC. 409
    • 19.28.1 COMPANY SNAPSHOT 409
    • 19.28.2 PRODUCT PORTFOLIO 409
    • 19.28.3 RECENT DEVELOPMENTS 409

20 QUESTIONNAIRE 410

21 RELATED REPORTS 414

LIST OF TABLES

  • TABLE 1 PIPELINE ANALYSIS FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET 82
  • TABLE 2 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 99
  • TABLE 3 GLOBAL PRIMARY (DE NOVO) IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 100
  • TABLE 4 GLOBAL SECONDARY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 101
  • TABLE 5 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 105
  • TABLE 6 GLOBAL SURGERY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 106
  • TABLE 7 GLOBAL RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 107
  • TABLE 8 GLOBAL RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 107
  • TABLE 9 GLOBAL MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 10 GLOBAL MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 109
  • TABLE 11 GLOBAL TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 109
  • TABLE 12 GLOBAL NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 110
  • TABLE 13 GLOBAL CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 110
  • TABLE 14 GLOBAL TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 111
  • TABLE 15 GLOBAL ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 112
  • TABLE 16 GLOBAL CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 112
  • TABLE 17 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 117
  • TABLE 18 GLOBAL ADULTS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 118
  • TABLE 19 GLOBAL ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 118
  • TABLE 20 GLOBAL GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 119
  • TABLE 21 GLOBAL GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 120
  • TABLE 22 GLOBAL CHILD IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 121
  • TABLE 23 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 24 GLOBAL GENERICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 126
  • TABLE 25 GLOBAL BRANDED IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 127
  • TABLE 26 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 131
  • TABLE 27 GLOBAL PARENTERAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 132
  • TABLE 28 GLOBAL ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 133
  • TABLE 29 GLOBAL ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 133
  • TABLE 30 GLOBAL OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 134
  • TABLE 31 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 138
  • TABLE 32 GLOBAL HOSPITAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 139
  • TABLE 33 GLOBAL CLINICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 140
  • TABLE 34 GLOBAL HOME HEALTHCARE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 140
  • TABLE 35 GLOBAL OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 141
  • TABLE 36 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 145
  • TABLE 37 GLOBAL HOSPITAL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 146
  • TABLE 38 GLOBAL RETAIL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 147
  • TABLE 39 GLOBAL ONLINE PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 147
  • TABLE 40 GLOBAL OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 148
  • TABLE 41 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 155
  • TABLE 42 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 161
  • TABLE 43 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 161
  • TABLE 44 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 161
  • TABLE 45 NORTH AMERICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 161
  • TABLE 46 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 162
  • TABLE 47 NORTH AMERICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 162
  • TABLE 48 NORTH AMERICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 162
  • TABLE 49 NORTH AMERICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 162
  • TABLE 50 NORTH AMERICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 163
  • TABLE 51 NORTH AMERICA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 163
  • TABLE 52 NORTH AMERICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 163
  • TABLE 53 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 163
  • TABLE 54 NORTH AMERICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 163
  • TABLE 55 NORTH AMERICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 56 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 57 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 164
  • TABLE 58 NORTH AMERICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 164
  • TABLE 59 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 164
  • TABLE 60 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 165
  • TABLE 61 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 62 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 166
  • TABLE 63 U.S. RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 166
  • TABLE 64 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 166
  • TABLE 65 U.S. TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 66 U.S. NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 67 U.S. CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 68 U.S. TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 69 U.S. ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 167
  • TABLE 70 U.S. CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 168
  • TABLE 71 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 72 U.S. ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 73 U.S. GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 74 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 75 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 169
  • TABLE 76 U.S. ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 169
  • TABLE 77 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 169
  • TABLE 78 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 169
  • TABLE 79 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 80 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 170
  • TABLE 81 CANADA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 170
  • TABLE 82 CANADA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 170
  • TABLE 83 CANADA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 84 CANADA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 85 CANADA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 86 CANADA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 87 CANADA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 171
  • TABLE 88 CANADA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 172
  • TABLE 89 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 90 CANADA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 91 CANADA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 92 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 93 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 173
  • TABLE 94 CANADA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 173
  • TABLE 95 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 173
  • TABLE 96 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 173
  • TABLE 97 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 98 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 174
  • TABLE 99 MEXICO RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 174
  • TABLE 100 MEXICO MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 174
  • TABLE 101 MEXICO TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 102 MEXICO NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 103 MEXICO CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 104 MEXICO TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 105 MEXICO ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 175
  • TABLE 106 MEXICO CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 176
  • TABLE 107 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 108 MEXICO ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 109 MEXICO GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 110 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 111 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 177
  • TABLE 112 MEXICO ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 177
  • TABLE 113 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 177
  • TABLE 114 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 177
  • TABLE 115 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 183
  • TABLE 116 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 183
  • TABLE 117 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 183
  • TABLE 118 EUROPE RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 184
  • TABLE 119 EUROPE MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 184
  • TABLE 120 EUROPE TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 184
  • TABLE 121 EUROPE NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 184
  • TABLE 122 EUROPE CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 123 EUROPE TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 124 EUROPE ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 125 EUROPE CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 126 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 185
  • TABLE 127 EUROPE ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 128 EUROPE GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 129 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 130 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 186
  • TABLE 131 EUROPE ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 186
  • TABLE 132 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 187
  • TABLE 133 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 187
  • TABLE 134 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 188
  • TABLE 135 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 188
  • TABLE 136 GERMANY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 188
  • TABLE 137 GERMANY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 188
  • TABLE 138 GERMANY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 139 GERMANY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 140 GERMANY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 141 GERMANY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 142 GERMANY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 143 GERMANY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 190
  • TABLE 144 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 145 GERMANY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 146 GERMANY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 147 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 148 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 191
  • TABLE 149 GERMANY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 191
  • TABLE 150 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 191
  • TABLE 151 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 191
  • TABLE 152 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 192
  • TABLE 153 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 192
  • TABLE 154 FRANCE RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 192
  • TABLE 155 FRANCE MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 192
  • TABLE 156 FRANCE TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 157 FRANCE NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 158 FRANCE CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 159 FRANCE TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 160 FRANCE ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 161 FRANCE CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 194
  • TABLE 162 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 163 FRANCE ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 164 FRANCE GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 165 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 166 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 195
  • TABLE 167 FRANCE ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 195
  • TABLE 168 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 195
  • TABLE 169 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 195
  • TABLE 170 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 196
  • TABLE 171 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 196
  • TABLE 172 U.K. RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 196
  • TABLE 173 U.K. MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 196
  • TABLE 174 U.K. TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 197
  • TABLE 175 U.K. NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 197
  • TABLE 176 U.K. CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 197
  • TABLE 177 U.K. TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 197
  • TABLE 178 U.K. ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 197
  • TABLE 179 U.K. CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 198
  • TABLE 180 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 198
  • TABLE 181 U.K. ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 198
  • TABLE 182 U.K. GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 198
  • TABLE 183 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 198
  • TABLE 184 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 199
  • TABLE 185 U.K. ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 199
  • TABLE 186 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 199
  • TABLE 187 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 199
  • TABLE 188 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 200
  • TABLE 189 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 200
  • TABLE 190 ITALY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 200
  • TABLE 191 ITALY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 200
  • TABLE 192 ITALY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 201
  • TABLE 193 ITALY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 201
  • TABLE 194 ITALY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 201
  • TABLE 195 ITALY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 201
  • TABLE 196 ITALY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 201
  • TABLE 197 ITALY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 202
  • TABLE 198 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 202
  • TABLE 199 ITALY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 202
  • TABLE 200 ITALY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 202
  • TABLE 201 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 202
  • TABLE 202 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 203
  • TABLE 203 ITALY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 203
  • TABLE 204 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 203
  • TABLE 205 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 203
  • TABLE 206 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 204
  • TABLE 207 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 204
  • TABLE 208 SPAIN RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 204
  • TABLE 209 SPAIN MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 204
  • TABLE 210 SPAIN TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 205
  • TABLE 211 SPAIN NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 205
  • TABLE 212 SPAIN CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 205
  • TABLE 213 SPAIN TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 205
  • TABLE 214 SPAIN ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 205
  • TABLE 215 SPAIN CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 206
  • TABLE 216 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 206
  • TABLE 217 SPAIN ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 206
  • TABLE 218 SPAIN GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 206
  • TABLE 219 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 206
  • TABLE 220 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 207
  • TABLE 221 SPAIN ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 207
  • TABLE 222 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 207
  • TABLE 223 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 207
  • TABLE 224 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 208
  • TABLE 225 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 208
  • TABLE 226 RUSSIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 208
  • TABLE 227 RUSSIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 208
  • TABLE 228 RUSSIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 209
  • TABLE 229 RUSSIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 209
  • TABLE 230 RUSSIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 209
  • TABLE 231 RUSSIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 209
  • TABLE 232 RUSSIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 209
  • TABLE 233 RUSSIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 210
  • TABLE 234 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 210
  • TABLE 235 RUSSIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 210
  • TABLE 236 RUSSIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 210
  • TABLE 237 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 210
  • TABLE 238 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 211
  • TABLE 239 RUSSIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 211
  • TABLE 240 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 211
  • TABLE 241 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 211
  • TABLE 242 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 212
  • TABLE 243 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 212
  • TABLE 244 SWITZERLAND RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 212
  • TABLE 245 SWITZERLAND MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 212
  • TABLE 246 SWITZERLAND TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 213
  • TABLE 247 SWITZERLAND NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 213
  • TABLE 248 SWITZERLAND CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 213
  • TABLE 249 SWITZERLAND TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 213
  • TABLE 250 SWITZERLAND ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 213
  • TABLE 251 SWITZERLAND CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 214
  • TABLE 252 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 214
  • TABLE 253 SWITZERLAND ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 214
  • TABLE 254 SWITZERLAND GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 214
  • TABLE 255 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 214
  • TABLE 256 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 215
  • TABLE 257 SWITZERLAND ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 215
  • TABLE 258 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 215
  • TABLE 259 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 215
  • TABLE 260 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 216
  • TABLE 261 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 216
  • TABLE 262 NETHERLANDS RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 216
  • TABLE 263 NETHERLANDS MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 216
  • TABLE 264 NETHERLANDS TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 217
  • TABLE 265 NETHERLANDS NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 217
  • TABLE 266 NETHERLANDS CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 217
  • TABLE 267 NETHERLANDS TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 217
  • TABLE 268 NETHERLANDS ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 217
  • TABLE 269 NETHERLANDS CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 218
  • TABLE 270 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 218
  • TABLE 271 NETHERLANDS ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 218
  • TABLE 272 NETHERLANDS GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 218
  • TABLE 273 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 218
  • TABLE 274 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 219
  • TABLE 275 NETHERLANDS ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 219
  • TABLE 276 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 219
  • TABLE 277 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 219
  • TABLE 278 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 220
  • TABLE 279 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 220
  • TABLE 280 HUNGARY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 220
  • TABLE 281 HUNGARY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 220
  • TABLE 282 HUNGARY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 221
  • TABLE 283 HUNGARY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 221
  • TABLE 284 HUNGARY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 221
  • TABLE 285 HUNGARY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 221
  • TABLE 286 HUNGARY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 221
  • TABLE 287 HUNGARY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 222
  • TABLE 288 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 222
  • TABLE 289 HUNGARY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 222
  • TABLE 290 HUNGARY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 222
  • TABLE 291 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 222
  • TABLE 292 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 223
  • TABLE 293 HUNGARY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 223
  • TABLE 294 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 223
  • TABLE 295 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 223
  • TABLE 296 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 224
  • TABLE 297 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 224
  • TABLE 298 POLAND RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 224
  • TABLE 299 POLAND MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 224
  • TABLE 300 POLAND TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 225
  • TABLE 301 POLAND NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 225
  • TABLE 302 POLAND CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 225
  • TABLE 303 POLAND TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 225
  • TABLE 304 POLAND ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 225
  • TABLE 305 POLAND CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 226
  • TABLE 306 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 226
  • TABLE 307 POLAND ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 226
  • TABLE 308 POLAND GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 226
  • TABLE 309 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 226
  • TABLE 310 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 227
  • TABLE 311 POLAND ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 227
  • TABLE 312 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 227
  • TABLE 313 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 227
  • TABLE 314 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 228
  • TABLE 315 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 228
  • TABLE 316 AUSTRIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 228
  • TABLE 317 AUSTRIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 228
  • TABLE 318 AUSTRIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 229
  • TABLE 319 AUSTRIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 229
  • TABLE 320 AUSTRIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 229
  • TABLE 321 AUSTRIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 229
  • TABLE 322 AUSTRIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 229
  • TABLE 323 AUSTRIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 230
  • TABLE 324 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 230
  • TABLE 325 AUSTRIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 230
  • TABLE 326 AUSTRIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 230
  • TABLE 327 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 230
  • TABLE 328 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 231
  • TABLE 329 AUSTRIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 231
  • TABLE 330 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 231
  • TABLE 331 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 231
  • TABLE 332 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 232
  • TABLE 333 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 232
  • TABLE 334 IRELAND RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 232
  • TABLE 335 IRELAND MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 232
  • TABLE 336 IRELAND TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 233
  • TABLE 337 IRELAND NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 233
  • TABLE 338 IRELAND CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 233
  • TABLE 339 IRELAND TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 233
  • TABLE 340 IRELAND ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 233
  • TABLE 341 IRELAND CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 234
  • TABLE 342 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 234
  • TABLE 343 IRELAND ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 234
  • TABLE 344 IRELAND GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 234
  • TABLE 345 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 234
  • TABLE 346 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 235
  • TABLE 347 IRELAND ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 235
  • TABLE 348 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 235
  • TABLE 349 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 235
  • TABLE 350 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 236
  • TABLE 351 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 236
  • TABLE 352 NORWAY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 236
  • TABLE 353 NORWAY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 236
  • TABLE 354 NORWAY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 237
  • TABLE 355 NORWAY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 237
  • TABLE 356 NORWAY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 237
  • TABLE 357 NORWAY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 237
  • TABLE 358 NORWAY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 237
  • TABLE 359 NORWAY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 238
  • TABLE 360 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 238
  • TABLE 361 NORWAY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 238
  • TABLE 362 NORWAY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 238
  • TABLE 363 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 238
  • TABLE 364 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 239
  • TABLE 365 NORWAY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 239
  • TABLE 366 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 239
  • TABLE 367 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 239
  • TABLE 368 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 240
  • TABLE 369 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 240
  • TABLE 370 LITHUANIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 240
  • TABLE 371 LITHUANIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 240
  • TABLE 372 LITHUANIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 241
  • TABLE 373 LITHUANIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 241
  • TABLE 374 LITHUANIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 241
  • TABLE 375 LITHUANIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 241
  • TABLE 376 LITHUANIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 241
  • TABLE 377 LITHUANIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 242
  • TABLE 378 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 242
  • TABLE 379 LITHUANIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 242
  • TABLE 380 LITHUANIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 242
  • TABLE 381 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 242
  • TABLE 382 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 243
  • TABLE 383 LITHUANIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 243
  • TABLE 384 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 243
  • TABLE 385 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 243
  • TABLE 386 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 244
  • TABLE 387 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 244
  • TABLE 388 TURKEY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 244
  • TABLE 389 TURKEY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 244
  • TABLE 390 TURKEY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 245
  • TABLE 391 TURKEY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 245
  • TABLE 392 TURKEY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 245
  • TABLE 393 TURKEY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 245
  • TABLE 394 TURKEY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 245
  • TABLE 395 TURKEY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 246
  • TABLE 396 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 246
  • TABLE 397 TURKEY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 246
  • TABLE 398 TURKEY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 246
  • TABLE 399 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 246
  • TABLE 400 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 247
  • TABLE 401 TURKEY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 247
  • TABLE 402 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 247
  • TABLE 403 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 247
  • TABLE 404 REST OF EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 248
  • TABLE 405 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 254
  • TABLE 406 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 254
  • TABLE 407 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 254
  • TABLE 408 ASIA-PACIFIC RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 255
  • TABLE 409 ASIA-PACIFIC MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 255
  • TABLE 410 ASIA-PACIFIC TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 255
  • TABLE 411 ASIA-PACIFIC NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 255
  • TABLE 412 ASIA-PACIFIC CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 256
  • TABLE 413 ASIA-PACIFIC TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 256
  • TABLE 414 ASIA-PACIFIC ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 256
  • TABLE 415 ASIA-PACIFIC CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 256
  • TABLE 416 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 256
  • TABLE 417 ASIA-PACIFIC ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 257
  • TABLE 418 ASIA-PACIFIC GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 257
  • TABLE 419 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 257
  • TABLE 420 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 257
  • TABLE 421 ASIA-PACIFIC ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 257
  • TABLE 422 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 258
  • TABLE 423 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 258
  • TABLE 424 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 259
  • TABLE 425 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 259
  • TABLE 426 JAPAN RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 259
  • TABLE 427 JAPAN MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 260
  • TABLE 428 JAPAN TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 260
  • TABLE 429 JAPAN NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 260
  • TABLE 430 JAPAN CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 260
  • TABLE 431 JAPAN TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 261
  • TABLE 432 JAPAN ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 261
  • TABLE 433 JAPAN CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 261
  • TABLE 434 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 261
  • TABLE 435 JAPAN ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 262
  • TABLE 436 JAPAN GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 262
  • TABLE 437 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 262
  • TABLE 438 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 262
  • TABLE 439 JAPAN ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 263
  • TABLE 440 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 263
  • TABLE 441 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 263
  • TABLE 442 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 264
  • TABLE 443 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 264
  • TABLE 444 CHINA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 264
  • TABLE 445 CHINA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 264
  • TABLE 446 CHINA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 265
  • TABLE 447 CHINA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 265
  • TABLE 448 CHINA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 265
  • TABLE 449 CHINA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 265
  • TABLE 450 CHINA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 265
  • TABLE 451 CHINA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 266
  • TABLE 452 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 266
  • TABLE 453 CHINA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 266
  • TABLE 454 CHINA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 266
  • TABLE 455 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 266
  • TABLE 456 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 267
  • TABLE 457 CHINA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 267
  • TABLE 458 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 267
  • TABLE 459 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 267
  • TABLE 460 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 268
  • TABLE 461 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 268
  • TABLE 462 INDIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 268
  • TABLE 463 INDIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 268
  • TABLE 464 INDIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 269
  • TABLE 465 INDIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 269
  • TABLE 466 INDIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 269
  • TABLE 467 INDIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 269
  • TABLE 468 INDIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 269
  • TABLE 469 INDIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 270
  • TABLE 470 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 270
  • TABLE 471 INDIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 270
  • TABLE 472 INDIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 270
  • TABLE 473 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 270
  • TABLE 474 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 271
  • TABLE 475 INDIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 271
  • TABLE 476 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 271
  • TABLE 477 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 271
  • TABLE 478 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 272
  • TABLE 479 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 272
  • TABLE 480 AUSTRALIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 272
  • TABLE 481 AUSTRALIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 272
  • TABLE 482 AUSTRALIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 273
  • TABLE 483 AUSTRALIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 273
  • TABLE 484 AUSTRALIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 273
  • TABLE 485 AUSTRALIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 273
  • TABLE 486 AUSTRALIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 273
  • TABLE 487 AUSTRALIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 274
  • TABLE 488 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 274
  • TABLE 489 AUSTRALIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 274
  • TABLE 490 AUSTRALIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 274
  • TABLE 491 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 274
  • TABLE 492 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 275
  • TABLE 493 AUSTRALIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 275
  • TABLE 494 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 275
  • TABLE 495 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 275
  • TABLE 496 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 276
  • TABLE 497 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 276
  • TABLE 498 SOUTH KOREA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 276
  • TABLE 499 SOUTH KOREA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 276
  • TABLE 500 SOUTH KOREA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 277
  • TABLE 501 SOUTH KOREA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 277
  • TABLE 502 SOUTH KOREA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 277
  • TABLE 503 SOUTH KOREA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 277
  • TABLE 504 SOUTH KOREA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 277
  • TABLE 505 SOUTH KOREA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 278
  • TABLE 506 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 278
  • TABLE 507 SOUTH KOREA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 278

LIST OF FIGURES

  • FIGURE 1 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 60
  • FIGURE 2 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET : DATA TRIANGULATION 63
  • FIGURE 3 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DROC ANALYSIS 64
  • FIGURE 4 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 65
  • FIGURE 5 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 65
  • FIGURE 6 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MULTIVARIATE MODELLING 66
  • FIGURE 7 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 67
  • FIGURE 8 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DBMR MARKET POSITION GRID 68
  • FIGURE 9 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MARKET END USER COVERAGE GRID 69
  • FIGURE 10 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: VENDOR SHARE ANALYSIS 70
  • FIGURE 11 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 74
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 75
  • FIGURE 13 INCREASE IN THE PREVALENCE OF GLIOBLASTOMA MULTIFORME AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 76
  • FIGURE 14 PRIMARY (DE NOVO) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN 2022 & 2029 76
  • FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 77
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET 87
  • FIGURE 17 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2021 97
  • FIGURE 18 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION) 98
  • FIGURE 19 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, CAGR (2022-2029) 98
  • FIGURE 20 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, LIFELINE CURVE 99
  • FIGURE 21 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2021 103
  • FIGURE 22 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION) 104
  • FIGURE 23 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, CAGR (2022-2029) 104
  • FIGURE 24 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, LIFELINE CURVE 105
  • FIGURE 25 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2021 115
  • FIGURE 26 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 116
  • FIGURE 27 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, CAGR (2022-2029) 116
  • FIGURE 28 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE 117
  • FIGURE 29 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2021 123
  • FIGURE 30 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 124
  • FIGURE 31 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029) 124
  • FIGURE 32 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE 125
  • FIGURE 33 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021 129
  • FIGURE 34 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 130
  • FIGURE 35 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 130
  • FIGURE 36 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 131
  • FIGURE 37 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2021 136
  • FIGURE 38 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION) 137
  • FIGURE 39 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, CAGR (2022-2029) 137
  • FIGURE 40 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, LIFELINE CURVE 138
  • FIGURE 41 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021 143
  • FIGURE 42 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 144
  • FIGURE 43 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 144
  • FIGURE 44 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 145
  • FIGURE 45 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021) 151
  • FIGURE 46 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021) 153
  • FIGURE 47 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 153
  • FIGURE 48 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 154
  • FIGURE 49 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022-2029) 154
  • FIGURE 50 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021) 157
  • FIGURE 51 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021) 159
  • FIGURE 52 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 159
  • FIGURE 53 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 160
  • FIGURE 54 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022-2029) 160
  • FIGURE 55 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021) 179
  • FIGURE 56 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021) 181
  • FIGURE 57 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 181
  • FIGURE 58 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 182
  • FIGURE 59 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022-2029) 182
  • FIGURE 60 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2022) 250
  • FIGURE 61 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022) 252
  • FIGURE 62 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 252
  • FIGURE 63 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 253
  • FIGURE 64 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022 & 2029) 253
  • FIGURE 65 SOUTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021) 306
  • FIGURE 66 SOUTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021) 308
  • FIGURE 67 SOUTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 308
  • FIGURE 68 SOUTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 309
  • FIGURE 69 SOUTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022-2029) 309
  • FIGURE 70 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021) 329
  • FIGURE 71 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021) 331
  • FIGURE 72 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 331
  • FIGURE 73 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 332
  • FIGURE 74 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022 & 2029) 332
  • FIGURE 75 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%) 355
  • FIGURE 76 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%) 356
  • FIGURE 77 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%) 357
  • FIGURE 78 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%) 358
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!